Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pluristem Therapeutics (PSTI) stock

Learn how to easily invest in Pluristem Therapeutics stock.

Pluristem Therapeutics Inc
-$0.08 (-2.41%)

Pluristem Therapeutics Inc is a biotechnology business based in the US. Pluristem Therapeutics shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem Therapeutics employs 146 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Pluristem Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PSTI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pluristem Therapeutics stock price (NASDAQ: PSTI)

Use our graph to track the performance of PSTI stocks over time.

Pluristem Therapeutics shares at a glance

Information last updated 2021-07-24.
Latest market close$3.68
52-week range$3.34 - $12.15
50-day moving average $3.92
200-day moving average $5.14
Wall St. target price$9.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.86

Buy Pluristem Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pluristem Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pluristem Therapeutics price performance over time

Historical closes compared with the close of $3.68 from 2021-05-28

1 week (2021-07-17) N/A
1 month (2021-06-28) -10.46%
3 months (2021-04-28) -18.58%
6 months (2021-01-24) N/A
1 year (2020-07-24) N/A
2 years (2019-07-24) N/A
3 years (2018-07-24) N/A
5 years (2016-07-24) N/A

Pluristem Therapeutics financials

Gross profit TTM $23,000
Return on assets TTM -54.49%
Return on equity TTM -105.54%
Profit margin 0%
Book value $2.15
Market capitalisation $108.9 million

TTM: trailing 12 months

Shorting Pluristem Therapeutics shares

There are currently 696,959 Pluristem Therapeutics shares held short by investors – that's known as Pluristem Therapeutics's "short interest". This figure is 127.7% up from 306,052 last month.

There are a few different ways that this level of interest in shorting Pluristem Therapeutics shares can be evaluated.

Pluristem Therapeutics's "short interest ratio" (SIR)

Pluristem Therapeutics's "short interest ratio" (SIR) is the quantity of Pluristem Therapeutics shares currently shorted divided by the average quantity of Pluristem Therapeutics shares traded daily (recently around 458525.65789474). Pluristem Therapeutics's SIR currently stands at 1.52. In other words for every 100,000 Pluristem Therapeutics shares traded daily on the market, roughly 1520 shares are currently held short.

However Pluristem Therapeutics's short interest can also be evaluated against the total number of Pluristem Therapeutics shares, or, against the total number of tradable Pluristem Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pluristem Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pluristem Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0254% of the tradable shares (for every 100,000 tradable Pluristem Therapeutics shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pluristem Therapeutics.

Find out more about how you can short Pluristem Therapeutics stock.

Pluristem Therapeutics share dividends

We're not expecting Pluristem Therapeutics to pay a dividend over the next 12 months.

Have Pluristem Therapeutics's shares ever split?

Pluristem Therapeutics's shares were split on a 1:10 basis on 24 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem Therapeutics shares which in turn could have impacted Pluristem Therapeutics's share price.

Pluristem Therapeutics share price volatility

Over the last 12 months, Pluristem Therapeutics's shares have ranged in value from as little as $3.34 up to $12.15. A popular way to gauge a stock's volatility is its "beta".

PSTI.US volatility(beta: 2.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem Therapeutics's is 2.339. This would suggest that Pluristem Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Pluristem Therapeutics overview

Pluristem Therapeutics Inc. , together with its subsidiary, Pluristem Ltd. , operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells.

Frequently asked questions

What percentage of Pluristem Therapeutics is owned by insiders or institutions?
Currently 13.924% of Pluristem Therapeutics shares are held by insiders and 20.042% by institutions.
How many people work for Pluristem Therapeutics?
Latest data suggests 146 work at Pluristem Therapeutics.
When does the fiscal year end for Pluristem Therapeutics?
Pluristem Therapeutics's fiscal year ends in June.
Where is Pluristem Therapeutics based?
Pluristem Therapeutics's address is: Building No. 5, Haifa, Israel, 31905
What is Pluristem Therapeutics's ISIN number?
Pluristem Therapeutics's international securities identification number is: US72940R3003
What is Pluristem Therapeutics's CUSIP number?
Pluristem Therapeutics's Committee on Uniform Securities Identification Procedures number is: 72940P106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site